Understand the source comparison
Comparison of ARA-290 and Standard Sarcoidosis Treatments in Research Models
The table below contrasts ARA-290 with conventional sarcoidosis therapies based on preclinical evidence and known mechanisms. This comparison highlights why researchers are exploring ARA-290 as an alternative or adjunct approach in granulomatous disease models
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below contrasts ARA-290 with conventional sarcoidosis therapies based on preclinical evidence and known mechanisms. This comparison highlights why researchers are exploring ARA-290 as an alternative or adjunct approach in granulomatous disease models.
- Corticosteroids (prednisone)
- Broad glucocorticoid receptor activation, suppresses NF-κB and cytokine transcription
- High. Affects all immune cells
- Significantly increased (opportunistic infections common)
- Reduces active inflammation but does not reverse established fibrosis
- Daily oral
- Gold standard for acute flares but long-term use causes osteoporosis, hyperglycemia, adrenal suppression. Taper required
- Methotrexate
- Folate antagonist, inhibits DHFR and T-cell proliferation
- Moderate. Primarily T-cells and rapidly dividing cells
- Moderately increased (monitor CBC)
- Minimal direct anti-fibrotic effect
- Weekly oral or subcutaneous
- Steroid-sparing agent with slower onset (8–12 weeks); requires folic acid supplementation and hepatic monitoring
- Infliximab (anti-TNF biologic)
- Monoclonal antibody neutralizes circulating and tissue TNF-α
- Moderate to high. TNF-α blockade affects granuloma maintenance and infection defense
- Significantly increased (TB reactivation, fungal infections)
- Reduces granuloma burden; limited fibrosis reversal data
- IV infusion every 4–8 weeks
- Effective for refractory cases but requires TB screening, expensive, and associated with infusion reactions and malignancy concerns
- ARA-290
- Innate repair receptor agonist, shifts macrophage phenotype from M1 to M2, modulates cytokine milieu
- Minimal. Preserves adaptive immunity and immune surveillance
- No documented increase in preclinical models
- Demonstrated reduction in fibroblast activation and collagen deposition in lung injury models
- Subcutaneous injection 2–3x weekly in research protocols
- Selective tissue-level modulation without systemic immunosuppression; limited human data but mechanistically distinct from all other options
- This comparison demonstrates why ARA-290 sarcoidosis research has gained attention: the peptide offers a mechanistic profile that none of the existing therapies replicate. Corticosteroids work but carry intolerable long-term side effects. Methotrexate and infliximab require significant monitoring and increase infection risk. ARA-290 targets the tissue microenvironment where granulomas form without disabling the immune system broadly.